Construction and validation of a seven-microRNA signature as a prognostic tool for lung squamous cell carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–485. doi:10.1016/S0140-6736(00)82038-310841143
   PubMed Web of Science ®Google Scholar
• Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The international association for the study of lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801. doi:10.1097/JTO.0b013e3181a7716e19458556
   PubMed Web of Science ®Google Scholar
• Sawabata N, Asamura H, Goya T, et al. Japanese lung cancer registry study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol. 2010;5(9):1369–1375. doi:10.1097/JTO.0b013e3181e452b920683209
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–859. doi:10.1097/JTO.0b013e318290868f23552377
   PubMed Web of Science ®Google Scholar
• Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer. 2007;43(10):1529–1544. doi:10.1016/j.ejca.2007.04.00217531469
   PubMed Web of Science ®Google Scholar
• Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539–3551. doi:10.1007/s00018-018-2877-x30030592
   PubMed Web of Science ®Google Scholar
• Legras A, Pecuchet N, Imbeaud S, et al. Epithelial-to-Mesenchymal transition and MicroRNAs in lung cancer. Cancers (Basel). 2017;9(8):101. doi:10.3390/cancers9080101
   PubMed Web of Science ®Google Scholar
• Florczuk M, Szpechcinski A, Chorostowska-Wynimko J. miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Target Oncol. 2017;12(2):179–200. doi:10.1007/s11523-017-0478-528243959
   PubMed Web of Science ®Google Scholar
• Lin Y, Lv Y, Liang R, et al. Four-miRNA signature as a prognostic tool for lung adenocarcinoma. Onco Targets Ther. 2018;11:29–36.29317831
   PubMed Web of Science ®Google Scholar
• Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69(14):5776–5783. doi:10.1158/0008-5472.CAN-09-058719584273
   PubMed Web of Science ®Google Scholar
• Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16(2):430–441. doi:10.1158/1078-0432.CCR-09-173620068076
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv00725605792
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344.10877287
   PubMed Web of Science ®Google Scholar
• Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–D152. doi:10.1093/nar/gku110425378301
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.21119131956
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.2133226742998
   PubMed Web of Science ®Google Scholar
• Soldera SV, Leighl NB. Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine. Front Oncol. 2017;7:50. doi:10.3389/fonc.2017.0005028396848
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838. doi:10.1038/nature0370215944708
   PubMed Web of Science ®Google Scholar
• Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57. doi:10.1016/j.ccr.2007.12.00818167339
   PubMed Web of Science ®Google Scholar
• Dvinge H, Git A, Graf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378–382. doi:10.1038/nature1210823644459
   PubMed Web of Science ®Google Scholar
• Lin P, Wen DY, Li Q, He Y, Yang H, Chen G. Genome-wide analysis of prognostic lncRNAs, miRNAs, and mRNAs forming a competing endogenous RNA network in hepatocellular carcinoma. Cell Physiol Biochem. 2018;48(5):1953–1967. doi:10.1159/00049251930092571
   PubMedGoogle Scholar
• Tan X, Qin W, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011;17(21):6802–6811. doi:10.1158/1078-0432.CCR-11-041921890451
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Y, Li Q, Fei X, Ma H, Hu R. miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9. Cancer Lett. 2019;446:81–89. doi:10.1016/j.canlet.2019.01.00730660651
   PubMed Web of Science ®Google Scholar
• Filipska M, Skrzypski M, Czetyrbok K, et al. MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer. 2018;118:111–118. doi:10.1016/j.lungcan.2018.02.00229571988
   PubMed Web of Science ®Google Scholar
• Luo P, Wang Q, Ye Y, et al. MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop. J Exp Clin Cancer Res. 2019;38(1):74. doi:10.1186/s13046-019-1079-130755230
   PubMedGoogle Scholar
• Gao X, Wu Y, Yu W, Li H. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma. Oncotarget. 2016;7(49):81670–81679. doi:10.18632/oncotarget.1316427835574
   PubMedGoogle Scholar
• Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. Cancer Manag Res. 2018;10:3463–3471. doi:10.2147/CMAR.S17048130254489
   PubMed Web of Science ®Google Scholar
• Nawaz Z, Patil V, Paul Y, et al. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. Mol Cancer. 2016;15(1):74. doi:10.1186/s12943-016-0557-827871300
   PubMedGoogle Scholar
• Liang X, Li Z, Men Q, Li Y, Li H, Chong T. miR-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1. Biomed Pharmacother. 2018;108:574–583. doi:10.1016/j.biopha.2018.09.05330243091
   PubMed Web of Science ®Google Scholar
• Jadideslam G, Ansarin K, Sakhinia E, Alipour S, Pouremamali F, Khabbazi A. The MicroRNA-326: autoimmune diseases, diagnostic biomarker, and therapeutic target. J Cell Physiol. 2018;233:9209s–9222. doi:10.1002/jcp.v233.1230078204
   PubMed Web of Science ®Google Scholar
• Yang Y, Li X, Yang Q, et al. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet. 2010;200(2):127–133. doi:10.1016/j.cancergencyto.2010.03.01420620595
   PubMedGoogle Scholar
• Jin X, Chen Y, Chen H, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311–5319. doi:10.1158/1078-0432.CCR-17-057728606918
   PubMed Web of Science ®Google Scholar